Real-Time PCR (qPCR) Market Research Report - Forecast till 2027

Real-Time PCR (qPCR) Market Research Report: Information by Product (Reagents & Consumables, Instruments, Software & Services), Application (Clinical, Research, and Forensics), End User (Hospitals &Diagnostic Centers, Research Laboratories & Academic Institutes, Pharmaceutical & Biotechnology Companies, Clinical Research Organizations, and Forensic Laboratories) - Forecast till 2027

ID: MRFR/HC/9188-HCR | September 2021 | Region: Global | 120 pages

Real-Time PCR (qPCR) Market Overview


The real-time PCR (qPCR) market is expected to cross ~USD 8,398.55 million in 2027 at a CAGR of ~8.92% during the forecast period. Real-Time PCR (qPCR) test is a qualitative detection of nucleic acid from the specimen of a patient suffering from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). Rising demand for real-time PCR (qPCR) for the treatment of ongoing COVID-19 outbreak and advancements in technology has enabled healthcare professionals to determine the infection level in real-time. This is one of the major factorsboosting the real-time PCR (qPCR) market growth. However, there are pitfalls in the Real-Time PCR (qPCR) market,such as complex regulatory scenarios, high cost, risk of eliciting false negative and positive results, and unaffordability of research fundings in emerging economies.


COVID-19 Analysis


The rising prevalenceof COVID-19 is projected to impact the real-time PCR (qPCR) market growth over the forecast period positively. As the coronavirus outbreak continues, the need for effective and quick testing is escalating the COVID-19 pandemic.The real-time PCR (qPCR) kit is considered one of the most sought-after methods in the healthcare industry, thereby producing a point in the demand for these kits. This factor is projected to have a positive impact on the real-time PCR (qPCR) market growth, which in turn also aids in driving the real-time PCR (qPCR) market growth.


Many research organizations and universities are giving outstanding support by providing real-time PCR (qPCR) platforms for conducting various tests, one of the most accurate laboratory methods for detecting, tracking, and studying the COVID-19 virus. Furthermore, government initiatives supporting the approvedreal-time PCR (qPCR) kits to help diagnose COVID-19 are also a boosting factor. For instance, the Indian government approved 12 rapid antibody test kits for COVID-19 diagnosis. The Indian Council Medical Research(ICMR)has also issued guidance on rapid antibody test kits for COVID-19.


Market Drivers


Rising demand for Real-Time PCR amid COVID-19 pandemic


The spike in the COVID-19 pandemichas triggered the demand for real-time PCR (qPCR) for rapid diagnosis.
Pharmaceutical companies are involved in R&D and are collaborating with other biotechnology companies. For instance, in September 2020, during the pandemic, Octapharma (Switzerland), one of the world’s leading manufacturers of therapeutic human proteins, chose Genedata’s (Switzerland) Genedata Selectoras its central computational platform to streamline next-generation sequencing-based real-time PCR (qPCR). The collaboration was carried out toshorten development cycles and increase efficiency. Such collaboration by the companies in the market is anticipated to propel real-time PCR (qPCR) market growth in the near future.
Moreover, the introduction of advanced technologies in the real-time PCR (qPCR) process is anticipated to propel real-time PCR (qPCR) market growth over the study period. For instance, in 2017, Bio-Rad Laboratories, Inc. (US)launched CFX Maestro Software for CFX Real-Time Instruments, a complete workflow solution for real-time PCR (qPCR) data collection and analysis. It integrates data visualization, statistical analysis, and publication-ready graphics production in one platform.


  • Increasing prevalence of target diseases and technological advancements in qPCR


Market Restraints



  • Risk of eliciting false-negative and false-positive results


According to apublished article in PubMed in April 2020, false-negative results may occur by mutations in the primer and probe-target regions in the SARS-CoV-2 genome. In addition, false-negative results may occur due to the presence of amplification inhibitors in the sample. Hence, the sensitivity and specificity of the RT-PCR test arenot 100% valid, which is limiting the growth of Real-Time PCR (qPCR) market. Many laboratory practice standards and personnel skills in the relevant technical and safety procedures often face false-negative results.


During the COVID-19 outbreak, testing of viral load kinetics in different anatomic sites of the patients, sampling procedures carried out by real-time PCR (qPCR) largely contribute to the false-negative results. False-negative results may occur due to amplification inhibitors present in the sample or insufficient organisms in the sample rising from inappropriate collection,transportation, or handling.


Market Opportunities



  • Growing market penetration in developing countries


Among many technological advancements in the medical industry, nucleic acid detection-based approaches have become a rapid and reliable technology for viral detection. The qualitative PCR method is considered the ‘gold standard’ for the detection of viruses and is characterized by high sensitivity, rapid detection, and specificity. Research fundings are being carried out in many countries to support COVID-19 treatment. For instance, in 2020,Pune-based Mylab Discovery developed a real-time PCR-based molecular diagnostic kit that screens and detects samples of patientshaving flu-like symptoms. The kit was developed and approved by ICMR and CDSCO, production of kits was ramped up in a short time from 30,000 tests to 2 lakhs tests per day.


Quantitative real-time PCR (qPCR) is of great interests due to its benefits as a specific and simple qualitative assay. Moreover, real-time (qPCR)has adequate sensitivity for diagnosing early infection.


Value Chain Analysis


The global real-time PCR (qPCR) market is growing steadily due to the emerging number of players in the marketinvolved in new product launches, acquisitions, and strategic collaborations. The value chain analysis of the real-time PCR (qPCR) market comprises four major components starting with the R&D and designing, followed by manufacturing the products, distribution & sales, and ends with post-sales services.


The R&D designing of real-time PCR (qPCR) starts with conceptualizing, followed by design, then development, and lastly, testing. The R&D segment comprises 25-30% of the value chain of real-time PCR (qPCR). After the product designs are final, the manufacturing of the product starts. Manufacturing consists of 35-40% of the value chain of real-time PCR (qPCR).


Segment Overview


By Product



  • Reagents & Consumables


The various reagents and assays used for real-time PCR assay are Template cDNA, Upstream and downstream primers, GoTaq DNA Polymerase with reaction buffer, dNTP mixture, Molecular grade, nuclease-free water, and Agarose. Increasing use of reagents and assays such as TaqMan Real-time PCR assays is expected to lead the market throughout the study period in this segment.


Real-Time consumables include plastics and supplies for qPCR experiments, including tubes, plates, caps, adhesive plate seals, strips, and racks. They are validated for optimal performance with the real-time PCR Systems. Increasing the use of these real-time PCR consumables to carry out various molecular procedures in real-time PCR systems is fueling the real-time PCR (qPCR) market growth of this segment.



  • Instruments


Rising efforts by PCR manufacturers to develop novel real-time PCR instrument systems and kits to use in molecular testing are projected to stimulate the growth for real-timePCR (qPCR) market. For instance, in January 2019, Qiagen N.V. developed the next-generation dPCR systems, and the company launched the system in 2020. In addition, the new system offers highly automated workflows and quicker turnaround time compared to current digital PCR platforms, which provided the company significant competitive advantage.



  • Software & Services


The software &services for real-time PCR (qPCR) helps to guides users towards sound and powerful data analysis. These softwaresare designed to streamline the process of real-time PCR data collection and analysis. The increasing use of these softwares for the accurate results of experiments conducted and for carrying out molecular procedures is fueling the real-time PCR (qPCR) market growth of this segment.


By Application



  • Clinical


The increasing number of acute and chronic diseases that require molecular testing is augmenting the market growth for the real-time PCR market. In addition, technological advancements in molecular assays and techniquesandthe proven efficacy ofreal-time PCR (qPCR)  analysis in the diagnosis have further enhanced the use of clinical diagnostic tests (including qPCR analysis). These factorsare supportingthe growth of this segment.



  • Research


Increasing usage of real-time PCR techniques in drug development and research activities is propelling the real-time PCR (qPCR) market growth of this segment. Increasing R&D spendings by many biotechnology & pharmaceutical companies is another key contributing factor for the market growth. For instance, In 2019, the global pharmaceutical industry spent USD 83 billion on R&D, which was observedtentimes what the industry spent per year in the 1980s. Thus, this rising investment in R&D is contributing towards driving this segment.



  • Forensics


DNA profiling (DNA testing, DNA typing,genetic fingerprinting) is a technique used by forensic scientists to identify an individual based on their DNA profile. Real-time PCR can be used as a tool in DNA fingerprinting. This technology can identify any person from millions which isanticipated to accelerate the real-time PCR (qPCR) market growth of this segment. Therefore, the rising adoption of real-time PCR for the DNA fingerprinting process is driving the real-time PCR (qPCR) market growth of this segment.



  • Others


The other applications of the real-time (qPCR) market include the food & beverage industry (F&B) and agriculture industry.Real-time (qPCR) is an important analytical method in food as well as in medical diagnostics. Increasing adoption of real-time (qPCR) in F&B industries and agriculture industriesto quantify crops is thus driving the real-time PCR (qPCR) market growth of this segment.


By End Users



  • Hospitals & Diagnostic Centers


Hospitals & diagnostic centers segment dominated the real-time PCR (qPCR) market owing to the ongoing expansion of healthcare infrastructure across emerging countries; increasing market availability of qPCR reagents& instruments in various clinical diagnostic applications;  high prevalence & incidence of target diseases such as HIV-AIDS, malaria, cancer, and tuberculosis; and rising awareness among end users related to the various advantages offered by real-time (qPCR) in rapid & effective disease diagnosis.



  • Research Laboratories & Academic Institutes


qPCR and dPCR systems are widely used in various research laboratories and academic institutes.The widespread use of these systems is attributed to features such as enhanced specificity and quick turnaround time. This factor, in turn, aids to boost the real-time PCR (qPCR) market growth of this segment.


Furthermore, the increasing use of real-time PCR (qPCR) instrument systemsin drug development will boost the real-time PCR (qPCR) market growth for real-time PCR (qPCR) products in biotechnology and pharmaceutical industries which is also contributing to the real-time PCR (qPCR) market growth during the study period.



  • Pharmaceutical & Biotechnology Companies


Real-time PCR (qPCR) is vital for the progression of drug discovery, enabling detection and quantification of various diseases, and it is commonly used in many pharmaceutical and biotechnology companies. This factor is acting as a key factor for the growth of this segment.



  • Clinical Research Organizations


The increasing adoption of real-time PCR for the number of clinical applications in many clinical research organizations has increased substantially. For instance, in the field of clinical microbiology, oncology, and gene therapy,real-time PCR (qPCR)  is a  standard method for disease detection, which is further acting as a key contributing factor for the growth of this segment.



  • Forensic Laboratories


The increasing number of qPCR assays being developed in single and multiplex modes for quantifying DNA in forensic samplesby the forensic laboratories is acting as a driving factor for the segment. These assays are developed to improve the accuracy and precision of DNA quantifications and provide tools to increase the efficiency and throughput of the analysis of forensic samples.


By Region



  • North America:


The market in North America accounted for the largest share in 2020 due to the presence of constant technological developments followed by discoveries triggering the adoption ofnovel methods of molecular methods by the major players of this region. The majormarket players such asABL SA Group (Luxembourg), Agilent Technologies, Inc. (US), Analytik Jena AG (Germany), BD (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland) are contributing to the real-time PCR (qPCR) market growth. For instance, in August 2020, Thermo Fisher Scientific Inc. (US) launched a highly automated, real-time PCR solution that is designed to analyze up to 6,000 samples in a day to meet the rising number of cases and testing required for the COVID-19 pandemic.



  • Europe:


The European real-time PCR (qPCR) market is driven by supportive government Real-Time PCR (qPCR) procedures and increasing demand for Real-Time PCR testing to fight against infectious diseases such as COVID-19. In addition, increasing demand for rapid diagnostics, rising prevalence of infectious and genetic disorders, and rapid technological advancements are driving the real-time PCR (qPCR) market growth of the real-time PCR (qPCR) market.



  • Asia-Pacific:


The Asia-Pacific is expected to witness rapid growth in the global real-time PCR (qPCR) market throughout the assessment period. The Asia-Pacific regional market is anticipated to witness lucrative growth due to the presence of government and private sector companies regulating biotechnology products. For instance, in India, the Department of Biotechnology (DBT), the Department of Science and Technology (DST), Department of Scientific & Industrial Research (DSIR) are regulating the production and guidelines for biotechnology products. These organizationsprovide guidelines related to manufacturing or transferring technology and generate manpower for production raising funds.



  • Rest of the World:


The real-time PCR (qPCR) market in the rest of the world is driven by technological development in manufacturing, screening technologies, the biotechnology industry, and assays. The increasing number of government initiatives for improving the healthcare sector is another factor boosting the growth of the real-time PCR (qPCR) market in this region.


Competitive Landscape


The real-time PCR (qPCR) market is profitable, both for existing players and new entrants. A substantial level of competitive rivalry is witnessed among the market players. Based on the analysis, market players have adopted different strategies and innovative research and development techniques to expand their business and secure their position in the global real-time PCR (qPCR) market. For instance, in 2018, Denali Therapeutics (US)entered into a partnership with Lonza (Switzerland) to develop and produce biologic medicines using the latter’s real-Time PCR (qPCR) technology GS Xceed.The prominent players are involved in product launches, strategic agreements, and joint ventures to mark their presence in the real-time PCR (qPCR) market.


Bio-rad Laboratories has robust industry experience and is one of the leading companies in the real-timePCR market. Furthermore, a high customer satisfaction level, exceptional performance in new markets, and a strong product portfolio add to the company’s competitive advantage. The company also has a strong clientele and is well established in the industry. The company is continuously involved in seminars, conferences, and trade fairs in several countries to generate awareness about its products.


Key Players



  • ABL SA Group(Luxembourg)

  • Agilent Technologies, Inc. (US)

  • Analytik Jena AG(Germany)

  • BD (US)

  • Bio-Rad Laboratories, Inc. (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Fluidigm Corporation(US)

  • Lumex Instruments(US)

  • Primerdesign Ltd(UK)

  • QIAGEN (Germany)

  • Takara Bio Inc. (Japan)

  • Thermo Fisher Scientific(US)

  • TOYOBO Inc. (Japan)

  • Vela Diagnostics (Singapore)


Recent Developments



  • In June 2020, Azure Biosystems (US) launched the Azure Cielo Real-time PCR instrument. This 96 well qPCR machine provides high performance, compact design, and intuitive workflow. The sensitivity and reproducibility of the Azure Biosystem have been dedicated to the genomics workflow.

  • In March 2020, Abbott (US)company launched the m2000 RealTime SARS-CoV-2 EUA test, which performs its operations on the m2000 RealTime System located in the hospital and reference labs globally. The Company aims to produce about 5 million tests per month.


Report Overview:


The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and theRest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter’s Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report


The scope of the global real-time PCR (qPCR)market study includes a market size analysis and a detailed analysis of the manufacturer’s products and strategies. The real-time PCR (qPCR) market has been segmented based on product, application, end user, and region.


Market Segmentation


Real-Time PCR (qPCR), by Product



  • Reagents &Consumables

  • Instruments

  • Software and Services


Real-Time PCR (qPCR), by Application



  • Clinical

  • Research

  • Forensics

  • Others


Real-Time PCR (qPCR), by End User



  • Hospitals &Diagnostic Centers

  • Research Laboratories & Academic Institutes

  • Pharmaceutical &Biotechnology Companies

  • Clinical Research Organizations

  • Forensic Laboratories


Real-Time PCR (qPCR), by Region



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America





Report Scope:
Report Attribute/Metric Details
  Market Size   2027:~USD 8,398.55 Million
  CAGR   ~8.92%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018&2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product and Application
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   • ABL SA Group (Luxembourg) • Agilent Technologies, Inc. (US) • Analytik Jena AG (Germany) • BD (US) • Bio-Rad Laboratories, Inc. (US) • F. Hoffmann-La Roche Ltd (Switzerland) • Fluidigm Corporation (US) • Lumex Instruments (US) • Primerdesign Ltd (UK) • QIAGEN (Germany) • Takara Bio Inc. (Japan) • Thermo Fisher Scientific (US) • TOYOBO Inc. (Japan) • Vela Diagnostics (Singapore)
  Key Market Opportunities   Increasing adoption of real-time PCR kits to overcome the pandemic situation
  Key Market Drivers   • Rising demand for Real-time PCR amid COVID-19 pandemic • Increasing prevalence of target diseases and technological advancements in qPCR


TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY PRODUCT

6.1. Overview

6.2. Reagents & Consumables

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3. Instruments

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4. Software & Services

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY APPLICATION

7.1. Overview

7.2. Clinical

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.3. Research

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.4. Forensics

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Diagnostic Centers

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.3. Research Laboratories and Academic Institutes

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.4. Pharmaceutical and Biotechnology Companies

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY REGION

9.1. Overview

9.2. North America

9.2.1. US

9.2.2. Canada

9.3. Europe

9.3.1. Germany

9.3.2. France

9.3.3. Italy

9.3.4. Spain

9.3.5. UK

9.3.6. Rest of Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Rest of the World

9.5.1. Middle East

9.5.2. Africa

9.5.3. Latin America

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Real-Time PCR (qPCR) Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Real-Time PCR (qPCR) Market

10.7. Key Developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger &Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income,2020

10.8.2. Major Players R&D Expenditure,2020

11. COMPANY PROFILES

11.1. ABL SA Group

11.1.1. Company Overview

11.1.2. Products Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Agilent Technologies Inc

11.2.1. Company Overview

11.2.2. Products Offered

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Analytik Jena AG

11.3.1. Company Overview

11.3.2. Products Offered

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. BD

11.4.1. Company Overview

11.4.2. Products Offered

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Bio-Rad Laboratories

11.5.1. Company Overview

11.5.2. Products Offered

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. F-Hoffman-La Roche Ltd.

11.6.1. Company Overview

11.6.2. Products Offered

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Fluidigm Corporation

11.7.1. Company Overview

11.7.2. Products Offered

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Lumex Instruments

11.8.1. Company Overview

11.8.2. Products Offered

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Primerdesign Ltd.

11.9.1. Company Overview

11.9.2. Products Offered

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Qiagen

11.10.1. Company Overview

11.10.2. Products Offered

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. ThermoFisher Scientific

11.11.1. Company Overview

11.11.2. Products Offered

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Takara Bio Inc.

11.12.1. Company Overview

11.12.2. Products Offered

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Toyobo Inc.

11.13.1. Company Overview

11.13.2. Products Offered

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. Vela Diagnostics

11.14.1. Company Overview

11.14.2. Products Offered

11.14.3. Financial Overview

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL REAL-TIME PCR (QPCR) MARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL REAL-TIME PCR (QPCR)MARKET ESTIMATES &FORECAST, 2018–2027 (USD MILLION)

TABLE 3 GLOBAL REAL-TIME PCR (QPCR) MARKET, BYPRODUCT, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 5 NORTH AMERICA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 6 NORTH AMERICA REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 7 US: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 8 US REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 9 CANADA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 10 CANADA REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 11 EUROPE: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 12 EUROPE: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 13 GERMANY: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 14 GERMANY: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 15 UK: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 16 UK: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 17 FRANCE: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 18 FRANCE: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 19 ITALY: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 20 ITALY: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 21 SPAIN: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 22 SPAIN: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 23 REST OF EUROPE: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 24 REST OF EUROPE: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 25 ASIA-PACIFIC: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 26 ASIA-PACIFIC: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION,2018–2027 (USD MILLION)

TABLE 27 INDIA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 28 INDIA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 29 CHINA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 30 CHINA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 31 JAPAN: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 32 JAPAN: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 33 AUSTRALIA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 34 AUSTRALIA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 35 SOUTH KOREA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 36 SOUTH KOREA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 37 REST OF ASIA-PACIFIC: REAL-TIME PCR (QPCR)MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 38 REST OF ASIA-PACIFIC: REAL-TIME PCR (QPCR)MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 39 REST OF THE WORLD: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 40 REST OF THE WORLD: REAL-TIME PCR (QPCR)MARKET, APPLICATION, 2018–2027 (USD MILLION)

TABLE 41 MIDDLE EAST: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 42 MIDDLE EAST: REAL-TIME PCR (QPCR)MARKET, APPLICATION, 2018–2027 (USD MILLION)

TABLE 43 AFRICA: REAL-TIME PCR (QPCR)MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 44 AFRICA: REAL-TIME PCR (QPCR)MARKET, APPLICATION,2018–2027 (USD MILLION)

TABLE 45 LATIN AMERICA: REAL-TIME PCR (QPCR)MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 46 LATIN AMERICA: REAL-TIME PCR (QPCR)MARKET, APPLICATION, 2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL REAL-TIME PCR (QPCR) MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL REAL-TIME PCR (QPCR) MARKET

FIGURE 4 GLOBAL REAL-TIME PCR (QPCR) MARKET SHARE, BY PRODUCT, 2020(%)

FIGURE 5 GLOBAL REAL-TIME PCR (QPCR)MARKET SHARE, BY APPLICATION, 2020(%)

FIGURE 6 GLOBAL REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)

FIGURE 7 NORTH AMERICA: REAL-TIME PCR (QPCR)MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 EUROPE: REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)

FIGURE 9 ASIA-PACIFIC: REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)

FIGURE 10 REST OF THE WORLD: REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)

FIGURE 11 GLOBAL REAL-TIME PCR (QPCR) MARKET: COMPANY SHARE ANALYSIS, 2020(%)

FIGURE 12 ABL SA GROUP: KEY FINANCIALS

FIGURE 13 ABL SA GROUP: SWOT ANALYSIS

FIGURE 14 AGILENT TECHNOLOGIES, INC: KEY FINANCIALS

FIGURE 15 AGILENT TECHNOLOGIES, INC:SWOT ANALYSIS

FIGURE 16 ANALYTIK JENA AG: KEY FINANCIALS

FIGURE 17 ANALYTIK JENA AG: SWOT ANALYSIS

FIGURE 18 BD: KEY FINANCIALS

FIGURE 19 BD: SWOT ANALYSIS

FIGURE 20 BIO-RAD LABORATORIES, INC.: KEY FINANCIALS

FIGURE 21 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS

FIGURE 22 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS

FIGURE 24 FLUIDIGM CORPORATION: KEY FINANCIALS

FIGURE 25 FLUIDIGM CORPORATIONSWOT ANALYSIS

FIGURE 26 LUMEX INSTRUMENTS: KEY FINANCIALS

FIGURE 27 LUMEX INSTRUMENTS: SWOT ANALYSIS

FIGURE 28 PRIMERDESIGN LTD: KEY FINANCIALS

FIGURE 29 PRIMERDESIGN LTD: SWOT ANALYSIS

FIGURE 30 QIAGEN: KEY FINANCIALS

FIGURE 31 QIAGEN: SWOT ANALYSIS

FIGURE 32 TAKARA BIO INC: KEY FINANCIALS

FIGURE 33 TAKARA BIO INC: SWOT ANALYSIS

FIGURE 34 THERMO FISHER SCIENTIFIC: KEY FINANCIALS

FIGURE 35 THERMO FISHER SCIENTIFIC: SWOT ANALYSIS

FIGURE 36 TOYOBO INC: KEY FINANCIALS

FIGURE 37 TOYOBO INC: SWOT ANALYSIS

FIGURE 38 VELA DIAGNOSTICS: KEY FINANCIALS

FIGURE 39 VELA DIAGNOSTICS: SWOT ANALYSIS



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.